{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:28:20Z","timestamp":1773912500790,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02100-y","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:24:47Z","timestamp":1772889887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2011life diagnostic and therapeutic approach to CLL\/SLL in tuscany: the 2025 consensus"],"prefix":"10.1007","volume":"26","author":[{"given":"Maria","family":"D\u2019Amato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Maria","family":"Rapolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Capochiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ciofini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Giachetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Maestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Papini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Pirrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"16","key":"2100_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","volume":"333","author":"C Rozman","year":"1995","unstructured":"Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052\u20137.","journal-title":"N Engl J Med"},{"key":"2100_CR2","unstructured":"The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute. Cancer fact sheets: chronic lym- phocytic leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed Sep 17, 2022."},{"issue":"3","key":"2100_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M, Chronic Lymphocytic L. 2025 update on the Epidemiology, Pathogenesis, Diagnosis, and therapy. Am J Hematol. 2025;100(3):450\u201380. https:\/\/doi.org\/10.1002\/ajh.27546.","journal-title":"Am J Hematol"},{"issue":"1","key":"2100_CR4","doi-asserted-by":"publisher","first-page":"e2015056","DOI":"10.4084\/mjhid.2015.056","volume":"7","author":"G Salvi","year":"2015","unstructured":"Salvi G, Innocenti I, Autore F, Laurenti L. Chronic lymphocytic leukaemia: census of patients treated in Italian haematology units. Mediterr J Hematol Infect Dis. 2015;7(1):e2015056. PMID: 26543525; PMCID: PMC4621181.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"2100_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research initiative on CLL (ERIC) & European society for clinical cell analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21595.","journal-title":"Cytometry B Clin Cytom"},{"issue":"48","key":"2100_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jncimonographs\/lgu001","volume":"2014","author":"SL Slager","year":"2014","unstructured":"Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lympho- cytic leukemia\/small lymphocytic lymphoma: the interlymph Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):41\u201351.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"20","key":"2100_CR7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2015-04-537498","volume":"126","author":"JR Cerhan","year":"2015","unstructured":"Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126(20):2265\u201373.","journal-title":"Blood"},{"issue":"10129","key":"2100_CR8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524\u201337.","journal-title":"Lancet"},{"issue":"24","key":"2100_CR9","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.4161\/cc.7.24.7245","volume":"7","author":"T Zenz","year":"2008","unstructured":"Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lympho- cytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle. 2008;7(24):3810\u20134.","journal-title":"Cell Cycle"},{"issue":"4","key":"2100_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ajh.24660","volume":"92","author":"J Delgado","year":"2017","unstructured":"Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375\u201380. https:\/\/doi.org\/10.1002\/ajh.24660.","journal-title":"Am J Hematol"},{"issue":"12","key":"2100_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","volume":"92","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393\u20137. https:\/\/doi.org\/10.1002\/ajh.24808.","journal-title":"Am J Hematol"},{"issue":"1","key":"2100_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treat- ment and follow-up. Ann Oncol. 2021;32(1):23\u201333.","journal-title":"Ann Oncol"},{"issue":"2","key":"2100_CR13","first-page":"185","volume":"18","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Byrd JC, Abramson JS, et al. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(2):185\u2013217.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2100_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.seminhematol.2014.05.004","volume":"51","author":"M Gruber","year":"2014","unstructured":"Gruber M, Wu CJ. Evolving Understanding of the CLL genome. Semin Hematol. 2014;51(3):177\u201387.","journal-title":"Semin Hematol"},{"issue":"12","key":"2100_CR15","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679\u2013705.","journal-title":"Am J Hematol"},{"issue":"1","key":"2100_CR16","first-page":"11","volume":"21","author":"M Bocchia","year":"2020","unstructured":"Bocchia M, Bosi A, Capochiani E, et al. Real-life diagnostic and therapeutic approach to CLL: a new proposal from an expert panel in Tuscany region. Farmeconomia Health Econom Ther Pathw. 2020;21(1):11\u20138.","journal-title":"Farmeconomia Health Econom Ther Pathw"},{"issue":"8","key":"2100_CR17","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1007\/s10238-023-01244-5","volume":"23","author":"C Barat\u00e8","year":"2023","unstructured":"Barat\u00e8 C, Sanna A, Benedetti E, et al. Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany. Clin Exp Med. 2023;23(8):4251\u201364. https:\/\/doi.org\/10.1007\/s10238-023-01244-5.","journal-title":"Clin Exp Med"},{"issue":"3","key":"2100_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394\u2013402. https:\/\/doi.org\/10.1111\/bjh.14785.","journal-title":"Br J Haematol"},{"issue":"6","key":"2100_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1056\/NEJMoa075290","volume":"359","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Bennett FL, O\u2019Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575\u201383. https:\/\/doi.org\/10.1056\/NEJMoa075290.","journal-title":"N Engl J Med"},{"issue":"2","key":"2100_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cyto.b.21722","volume":"96","author":"A Mora","year":"2019","unstructured":"Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2019;96(2):143\u20138.","journal-title":"Cytometry B Clin Cytom"},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.blre.2022.100930","volume":"54","author":"NE Kay","year":"2022","unstructured":"Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev. 2022;54:100930. https:\/\/doi.org\/10.1016\/j.blre.2022.100930.","journal-title":"Blood Rev"},{"issue":"11","key":"2100_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M, et al. Diagnosis and treatment of chronic lymphocytic leukemia: A review. JAMA. 2023;329(11):918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"2","key":"2100_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminhematol.2024.01.003","volume":"61","author":"ER Francis","year":"2024","unstructured":"Francis ER, Vu J, Perez CO, Sun C. Vaccinations in patients with chronic lymphocytic leukemia. Semin Hematol. 2024;61(2):131\u20138. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.003.","journal-title":"Semin Hematol"},{"issue":"10453","key":"2100_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","volume":"404","author":"N Jain","year":"2024","unstructured":"Jain N, Wierda WG, O\u2019Brien S. Chronic lymphocytic leukaemia. Lancet. 2024;404(10453):694\u2013706. https:\/\/doi.org\/10.1016\/S0140-6736(24)00595-6.","journal-title":"Lancet"},{"key":"2100_CR25","doi-asserted-by":"publisher","unstructured":"Vitale C, Salvetti C, Griggio V, Porrazzo et al. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood. 2021;137(25):3507\u20133517. https:\/\/doi.org\/10.1182\/blood.2020008201. PMID: 33651883.","DOI":"10.1182\/blood.2020008201"},{"issue":"17","key":"2100_CR26","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","volume":"27","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Kaempf A, Sitlinger A, et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): A Three-Factor comorbidity model. Clin Cancer Res. 2021;27(17):4814\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3993.","journal-title":"Clin Cancer Res"},{"key":"2100_CR27","doi-asserted-by":"publisher","first-page":"12038","DOI":"10.1200\/JCO.2021.39.15_suppl.12038","volume":"39","author":"Federica","year":"2021","unstructured":"Federica, Biello, et al. Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies. J Clin Oncol. 2021;39:12038\u201312038. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.12038.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2100_CR28","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6(18):5516\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2022007938.","journal-title":"Blood Adv"},{"issue":"25","key":"2100_CR29","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, et al. Ibrutinib-Mediated atrial fibrillation attributable to Inhibition of C-Terminal Src kinase. Circulation. 2020;142(25):2443\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049210.","journal-title":"Circulation"},{"issue":"2","key":"2100_CR30","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1016\/S2152-2650(22)01324-6","volume":"22","author":"JR Brown","year":"2022","unstructured":"Brown JR, Hillmen P, Eichhorst B, et al. CLL-115 first interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lympho- cytic lymphoma (CLL\/SLL). Clin Lymphoma Myeloma Leuk. 2022;22(2):S266.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2100_CR31","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/1078155218785983","volume":"25","author":"CJ Kapelios","year":"2019","unstructured":"Kapelios CJ, Bonou MS, Diamantopoulos P, Angelopoulou MK, Masoura C, Barbetseas J, Viniou NA. Ibrutinib-related atrial fibrillation: therapeutic challenges. J Oncol Pharm Pract. 2019;25(5):1258\u201360. Epub 2018 Jul 17. PMID: 30012045.","journal-title":"J Oncol Pharm Pract"},{"key":"2100_CR32","unstructured":"Gonz\u00e1lez-Gasc\u00f3n Y, Mar\u00edn I, Hern\u00e1ndez-S\u00e1nchez M. December Prognostic Biomarkers of CLL. Encyclopedia. Available online: https:\/\/encyclopedia.pub\/entry\/9041 (accessed on 18 2025)."},{"issue":"5","key":"2100_CR33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","volume":"9","author":"JD Soumerai","year":"2025","unstructured":"Soumerai JD, Barrientos J, Ahn I, et al. Consensus recommendations from the 2024 lymphoma research foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025;9(5):1213\u201329. https:\/\/doi.org\/10.1182\/bloodadvances.2024014474.","journal-title":"Blood Adv"},{"issue":"3","key":"2100_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.htct.2023.05.006","volume":"45","author":"M Guarana","year":"2023","unstructured":"Guarana M, Nucci M. Infections in patients with chronic lymphocytic leukemia. Hematol Transfus Cell Ther. 2023;45(3):387\u201393. https:\/\/doi.org\/10.1016\/j.htct.2023.05.006.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"10","key":"2100_CR35","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2020007039","volume":"137","author":"A Agathangelidis","year":"2021","unstructured":"Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137(10):1365\u201376.","journal-title":"Blood"},{"issue":"4","key":"2100_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/joim.12455","volume":"279","author":"P Baliakas","year":"2016","unstructured":"Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Prog- nostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med. 2016;279(4):347\u201357.","journal-title":"J Intern Med"},{"issue":"1","key":"2100_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, et al. A new prognostic classifi- cation of chronic lymphocytic leukemia derived from a multivari- ate survival analysis. Cancer. 1981;48(1):198\u2013206.","journal-title":"Cancer"},{"issue":"5","key":"2100_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bjh.18075","volume":"197","author":"R Walewska","year":"2022","unstructured":"Walewska R, Parry-Jones N, Eyre TA, et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2022;197(5):544\u201357.","journal-title":"Br J Haematol"},{"key":"2100_CR39","doi-asserted-by":"publisher","first-page":"106564","DOI":"10.1016\/j.ejps.2023.106564","volume":"189","author":"C Li","year":"2023","unstructured":"Li C, Chen L, Li L, Chen W. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir\/ritonavir (paxlovid) based on physiologically-based Pharmacokinetic models. Eur J Pharm Sci. 2023;189:106564. https:\/\/doi.org\/10.1016\/j.ejps.2023.106564. Epub 2023 Aug 14. PMID: 37586436.","journal-title":"Eur J Pharm Sci"},{"key":"2100_CR40","doi-asserted-by":"publisher","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-Duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med Published Online Dec. 2025;6. https:\/\/doi.org\/10.1056\/NEJMoa2515458).","DOI":"10.1056\/NEJMoa2515458)"},{"key":"2100_CR41","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1038\/ncomms11589","volume":"7","author":"J Burger","year":"2016","unstructured":"Burger J, Landau D, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK Inhibition. Nat Commun. 2016;7:11589. https:\/\/doi.org\/10.1038\/ncomms11589.","journal-title":"Nat Commun"},{"key":"2100_CR42","doi-asserted-by":"publisher","unstructured":"Tam CS, Ghia P, Shadman M, et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). J Clin Oncol. 2025;43(suppl 16). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7011.","DOI":"10.1200\/JCO.2025.43.16_suppl.7011"},{"issue":"4","key":"2100_CR43","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acala- brutinib with or without obinutuzumab versus obinutuzumab plus Chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171\u20135.","journal-title":"Leukemia"},{"issue":"11","key":"2100_CR44","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350.","journal-title":"Blood Adv"},{"issue":"2","key":"2100_CR45","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/S2152-2650(22)01339-8","volume":"22","author":"O Al-Sawaf","year":"2022","unstructured":"Al-Sawaf O, Zhang C, Robrecht S, et al. CLL-246 venetoclax- obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. Clin Lymphoma Myeloma Leuk. 2022;22(2):S274\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"36","key":"2100_CR46","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049\u201360.","journal-title":"J Clin Oncol"},{"issue":"34","key":"2100_CR47","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: pri- Mary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853\u201365.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2100_CR48","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib- venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1(7):EVIDoa2200006.","journal-title":"NEJM Evid"},{"issue":"1","key":"2100_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"2020","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor Lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2020;2020(1):357\u201362. https:\/\/doi.org\/10.1182\/hematology.2020000120.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"26","key":"2100_CR50","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood.2025028550","volume":"146","author":"F Simon","year":"2025","unstructured":"Simon F, Ligtvoet R, Bohn JP, et al. Acalabrutinib treatment for older (aged\u2009\u2265\u200980 years) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial. Blood. 2025;146(26):3153\u201362. https:\/\/doi.org\/10.1182\/blood.2025028550.","journal-title":"Blood"},{"issue":"9","key":"2100_CR51","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","volume":"39","author":"P Blombery","year":"2025","unstructured":"Blombery P, Chatzikonstantinou T, et al. ERIC, the European research initiative on CLL. Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice. Leukemia. 2025;39(9):2049\u201360. https:\/\/doi.org\/10.1038\/s41375-025-02662-y. Epub 2025 Jun 24. PMID: 40555733; PMCID: PMC12380600.","journal-title":"Leukemia"},{"issue":"5","key":"2100_CR52","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","volume":"28","author":"AR Mato","year":"2017","unstructured":"Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leuke- mia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050\u20136.","journal-title":"Ann Oncol"},{"issue":"34","key":"2100_CR53","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042\u201354.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2100_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161.","journal-title":"Blood Cancer J"},{"issue":"25","key":"2100_CR55","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood.2020004782","volume":"135","author":"VS Lin","year":"2020","unstructured":"Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135(25):2266\u201370.","journal-title":"Blood"},{"issue":"4","key":"2100_CR56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000510768","volume":"144","author":"P Smolewski","year":"2021","unstructured":"Smolewski P, Robak T. Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs. Acta Hae- Matol. 2021;144(4):365\u201379.","journal-title":"Acta Hae- Matol"},{"issue":"6","key":"2100_CR57","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/CCO.0000000000000897","volume":"34","author":"F Perutelli","year":"2022","unstructured":"Perutelli F, Montalbano MC, Boccellato E, Coscia M, Vitale C. Beyond ibrutinib: novel BTK inhibitors for the treat- ment of chronic lymphocytic leukemia. Curr Opin Oncol. 2022;34(6):757\u201367.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"2100_CR58","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/jcm11113206","volume":"11","author":"E Benedetti","year":"2022","unstructured":"Benedetti E, Mavilia F, Barat\u00e8 C, et al. A prospective cross- sectional study on the comparison of ultrasound assessment vs. palpation in chronic lymphocytic leukemia patients in the era of targeted therapy. J Clin Med. 2022;11(11):3206.","journal-title":"J Clin Med"},{"issue":"10277","key":"2100_CR59","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet"},{"issue":"6","key":"2100_CR60","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11864-022-00974-0","volume":"23","author":"E Iskierka-Jazdzewska","year":"2022","unstructured":"Iskierka-Jazdzewska E, Obracaj A, Urbaniak M, Robak T. New treatment options for newly-diagnosed and relapsed chronic lymphocytic leukemia. Curr Treat Options Oncol. 2022;23(6):775\u201395.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"2100_CR61","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood.2021011516","volume":"139","author":"BMC Jebaraj","year":"2022","unstructured":"Jebaraj BMC, Muller A, Dheenadayalan RP, et al. Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibi- Tion for treatment of chronic lymphocytic leukemia. Blood. 2022;139(6):859\u201375.","journal-title":"Blood"},{"issue":"10","key":"2100_CR62","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","volume":"132","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, Muhowski EM, Guinn D, et al. Noncovalent inhi- bition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132(10):1039\u201349.","journal-title":"Blood"},{"issue":"3","key":"2100_CR63","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/cancers14030771","volume":"14","author":"T Robak","year":"2022","unstructured":"Robak T, Witkowska M, Smolewski P. The role of bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers. 2022;14(3):771.","journal-title":"Cancers"},{"issue":"Supplement 1","key":"2100_CR64","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1182\/blood-2024-205775","volume":"144","author":"A Jennifer","year":"2024","unstructured":"Jennifer A, Woyach DM, Brander, Boyu Hu KA, Rogers Z, Omer DM, Stephens A, Sitlinger F, Tan Y, Chen SP, Anthony Y, Chen K, Shang JC, Byrd. LP-168 (Rocbrutinib), a novel covalent and Non-Covalent Next-Generation inhibitor of bruton\u2019s tyrosine kinase: updates on the phase 1 trial and initial results of the CLL gatekeeper mutation cohort. Blood. 2024;144(Supplement 1):4622. https:\/\/doi.org\/10.1182\/blood-2024-205775.","journal-title":"Blood"},{"issue":"7","key":"2100_CR65","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO-24-02503","volume":"43","author":"MS Davids","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL, et al. Phase II study of Acalabrutinib, Venetoclax, and obinutuzumab in a Treatment-Na\u00efve chronic lymphocytic leukemia population enriched for High-Risk disease. J Clin Oncol. 2025;43(7):788\u201399. https:\/\/doi.org\/10.1200\/JCO-24-02503.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2100_CR66","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, et al. Fixed-Duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2409804.","journal-title":"N Engl J Med"},{"key":"2100_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00196-7)","author":"Moritz","year":"2024","unstructured":"Moritz, F\u00fcrstenau, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Published June. 2024. https:\/\/doi.org\/10.1016\/S1470-2045(24)00196-7).","journal-title":"Published June"},{"issue":"11","key":"2100_CR68","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms22115536","volume":"22","author":"V Mancikova","year":"2021","unstructured":"Mancikova V, Smida M. Current state of CAR T-cell therapy in chronic lymphocytic leukemia. Int J Mol Sci. 2021;22(11):5536.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2100_CR69","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood"},{"issue":"24","key":"2100_CR70","first-page":"3364","volume":"137","author":"Y Sun","year":"2021","unstructured":"Sun Y, et al. Targeted degradation of BTK in CLL models using protacs overcomes resistance to BTK inhibitors. Blood. 2021;137(24):3364\u201375.","journal-title":"Blood"},{"key":"2100_CR71","unstructured":"Baird JH, Hill BT et al. NX-2127, a first-in-class oral BTK degrader, demonstrates clinical activity in relapsed\/refractory B cell malignancies including BTKi-resistant CLL. Abstract #1364, ASH 2022 Annual Meeting."},{"key":"2100_CR72","unstructured":"Mato AR, Shah NN et al. Phase 1 first-in-human study of NX-5948, an oral BTK degrader, in patients with relapsed\/refractory B-cell malignancies. Abstract #3009, ASCO 2023 Annual Meeting."},{"key":"2100_CR73","first-page":"1261","volume":"37","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Overcoming resistance mutations in BTK using novel BTK-targeting degraders in preclinical CLL models. Leukemia. 2023;37:1261\u201372.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"2100_CR74","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2023-180109","volume":"142","author":"F John","year":"2023","unstructured":"John F, Seymour, et al. First results from a phase 1, First-in-Human study of the bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-Cell malignancies (BGB-16673-101). Blood. 2023;142(Supplement 1):4401. https:\/\/doi.org\/10.1182\/blood-2023-180109.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2100_CR75","first-page":"4315","volume":"130","author":"AR Mato","year":"2017","unstructured":"Mato AR, Tam CS, Allan JN, et al. Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients. Blood. 2017;130(Suppl 1):4315.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02100-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:57:16Z","timestamp":1773896236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02100-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}